HCP Perceptions, Attitudes and Intentions by Biosimilar Disclosure Characteristics
| Control | Kesterin is a Biosimilar | Kesterin is a Biosimilar + Effective | Kesterin is a Biosimilar + Effective + Same Sources | Kesterin is a Biosimilar + Effective + Same Sources + Dosage and Administration | Names the Reference Drug Mytrozen in Definition | Does Not Name Reference Drug in Definition | |
|---|---|---|---|---|---|---|---|
| Perceived benefit/efficacy | |||||||
| Benefit likelihood | 3.56 (1.16) | 3.59 (0.91) | 3.84 (0.97) | 3.94 (1.01) | 3.82 (1.19) | 3.86 (1.18) | 3.87 (0.95) |
| Benefit magnitude | 3.49 (1.16) | 3.54 (0.96) | 3.77 (0.97) | 3.89 (1.04) | 3.77 (1.09) | 3.71 (1.09) | 3.91 (0.98) |
| Benefit compared to Mytrozen | N/A | N/A | 2.66 (1.24) | 2.94 (1.45) | 2.83 (1.23) | N/A | 2.81 (1.3) |
| Benefit compared to other drugs | 3.42 (1.14) | 3.54 (0.89) | 3.16 (1.12) | 3.28 (1.28) | 3.30 (1.32) | 3.27 (1.31) | 3.23 (1.18) |
| Perceived risk/safety | |||||||
| Side effect likelihood | 3.37 (0.8) | 3.63 (0.77) | 3.54 (0.94) | 3.61 (0.98) | 3.72 (1.12) | 3.58 (1.15) | 3.67 (0.89) |
| Side effect severity | 3.35 (1.11) | 3.37 (1.02) | 3.53 (0.94) | 3.47 (1.00) | 3.60 (1.06) | 3.50 (1.09) | 3.57 (0.91) |
| Safety compared to Mytrozen | N/A | N/A | 2.78 (1.26) | 2.89 (1.43) | 2.88 (1.28) | N/A | 2.86 (1.32) |
| Safety compared to other drugs | 3.53 (1.00) | 3.63 (1.02) | 3.10 (1.12) | 3.31 (1.25) | 3.33 (1.30) | 3.28 (1.28) | 3.23 (1.18) |
| Attitudes toward the biosimilar drug | 3.80 (0.93) | 3.83 (0.97) | 4.21 (1.02) | 4.37 (1.03) | 4.12 (1.07) | 4.18 (1.43) | 4.41 (1.3) |
| Intention to prescribe biosimilar drug | 3.21 (1.36) | 3 (1.23) | 3.57 (1.30) | 3.84 (1.11) | 3.84 (1.37) | 4.27 (1.07) | 4.20 (1.02) |
| Perception that Kesterin and original biologic can be used “interchangeably” | N/A | N/A | 4.18 (1.40) | 4.37 (1.37) | 4.34 (1.35) | 4.62 (1.16) | 4.90 (1.24) |
Abbreviation: HCP, Health care providers.
Note: All planned comparisons were statistically nonsignificant at the Bonferonni adjusted levels. Items measured on a 1-6 Likert sale where larger values reflect stronger perceptions or agreement.